As part of our ongoing SUDEP Risk Assessment and Prevention Initiative, CURE Epilepsy is proud to announce a total of $750,000 in funding to three teams receiving a SUDEP Clinical Biomarker Team Science Award. The award is made possible through a lead gift from the Epilepsy Foundation as well as families who’ve experienced SUDEP.
The goal of the collaboration, which brings new researchers and disciplines into the epilepsy field, is to more effectively identify those who are at high risk of SUDEP and ultimately prevent this tragedy. A key outcome will be the development of a SUDEP Knowledge Base that will use cutting-edge AI technology to consolidate all research on SUDEP for use across disciplines.
SUDEP Clinical Biomarker Team Science Award Grantees
Andrew Landstrom, MD, PhD, Children's Hospital of Philadelphia
This project aims to identify which children are at highest risk and which medications are safest, with the goal of preventing sudden death and providing families and guiding clinical care of patients.
Learn More
Shobi Sivathamboo, PhD, Monash University, Melbourne
By analyzing patterns in heart rhythm, breathing, brain activity, arousal, and sleep, this project aims to uncover measurable warning signs of SUDEP risk to inform prevention strategies.
Learn More
Satya Sahoo, PhD, Case Western Reserve University
Using advanced artificial intelligence, this team aims to make advances that will facilitate the development of a personalized risk prediction tool that can estimate an individual’s SUDEP risk and clearly explain the reasons behind it.
Learn MoreMore CURE Epilepsy News
